Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16943373 | 0.87 | RAB9A (0.56) | APPNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3468767 | 0.85 | MAPT (0.65) | APPNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8735567 | 0.85 | MAPT (0.62) | APPNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2708042 | 0.84 | SCN4A (0.71) | APPNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3468668 | 0.82 | MAPT (0.61) | APPNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3468725 | 0.81 | MAPT (0.67) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21154647 | 0.79 | RAB9A (0.70) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21154016 | 0.79 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL21114767 | 0.79 | RAB9A (0.76) | NPC1RAB9ASMN1; SMN2MAPTGAA | |
| SCHEMBL14824499 | 0.79 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9174976-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-8759373-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2476669-A1 | Cyanoisoquinoline compounds and methods of use thereof | Fibrogen, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2044028-B1 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | FIBROGEN, INC. | 2011-09-01 | — | — | US | disclosed |
| US-7928120-B2 | Cyanoisoquinoline compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2044028-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007090068-A2 | CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) | FIBROGEN, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009653-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | APP 2622/4885NPC1 2027/4885RAB9A 4769/4885 |
| US-20070298104-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | APP 3674/4885NPC1 1650/4885RAB9A 4712/4885 |
| US-20120178755-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | APP 3674/4885NPC1 1650/4885RAB9A 4712/4885 |
| US-20150031696-A1 | CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN3 | APP 3674/4885NPC1 1650/4885RAB9A 4712/4885 |
| US-20110212959-A1 | Cyanoisoquinoline Compounds and Methods of Use Thereof | HIF1AN, HIF1A, EGLN3 | APP 3674/4885NPC1 1650/4885RAB9A 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.